ActaCell is an Austin-based technology start-up commercializing lithium-ion battery technology developed at The University of Texas at Austin.  ActaCell is pioneering innovations in battery technology that enable safe, high-performance, and long lasting rechargeable batteries at a low cost – helping the automotive industry overcome the most significant hurdle to creating commercially viable plug-in electric and hybrid-electric vehicles.

GlycosBio is transforming the fuels and chemicals industries with biological systems that can flexibly manufacture high value products from a wide range of non-food feedstocks.  The company has acquired and developed a platform technology that enables low cost production of chemicals with environmentally friendly technologies as an alternative to petrochemical-based manufacturing. Products envisioned include replacement of existing polymers with chemically equivalent polymers entirely derived from renewable resources.

Illumitex is an LED manufacturing company utilizing a novel approach to LED production that allows huge improvements in efficiency for display and general illumination applications.  Illumitex’ current and next-generation products will provide efficiencies that are 5-10 years ahead of the DOE roadmap for expected LED performance improvements.

Imagnx, Inc. is a next-generation, magnetic resonance imaging (MRI) company focusing on disease-specific MR imaging for cancer, Alzheimer’s and other CNS degenerative diseases. The Company is in the process of commercializing major university and research center technology, based on non-toxic and non-radioactive isotopes. Imagnx is currently in stealth mode.

Marval Biosciences develops novel CT contrast agents that reduce toxicity to patients and improve imaging performance. These next-generation contrast agents will enable a much broader population of patients to use CT for diagnosis of cardiovascular diseases without fear of contrast-induced nephropathy, which can cause acute kidney failure, particularly in elderly and diabetic patients. Based in Houston, Texas, Marval was created through the licensing of intellectual property from the University of Texas Health Science Center at Houston, Georgia Institute of Technology, Case Western Reserve University, Cleveland State University and The University of Houston.